Based on these outcomes, last week funding was announced to continue the next steps in evaluating ambroxol in a much larger cohort of people with Parkinson's, while also seeking to learn more about how individual patient genotypes may contribute to the disease.

鉴于已经取得的成果，上周宣布拨款继续下一步工作，在更大范围的帕金森患者中对氨溴索进行评估，同时争取更多地了解个体患者基因型对这种疾病的影响。

"The ambroxol study is important because there are no treatments available for Parkinson's that slow, stop, or reverse [it]" says Simon Stott, deputy director of research at The Cure Parkinson's Trust, one of the bodies funding the research program.

The Cure Parkinson的信托基金是资助这一研究项目的机构之一，研究副主任Simon Stott说：“氨溴索的研究非常重要，因为没有其他治疗方法能像它这样延缓、抑制或逆转帕金森病。”

"All of the current medications only deal with the symptoms of the condition – they do nothing to delay the progression of Parkinson's."

“目前所有药物只是对症，但不能控制病情发展。”

【止咳糖浆有望治疗帕金森?】相关文章：

★ 3D打印机有望“打印”出人体器官

★ 低头看手机的问题太严重，年轻人长出多余的骨头

★ 日本外相喊话外媒：安倍晋三的正确写法应该是Abe Shinzo

★ 为什么老公需要多做家务?

★ 做个成年人有哪些好处?

★ 快来看看自己的睡姿是否正确?

★ 《生活大爆炸》即将落幕 大结局精彩看点抢鲜知

★ 儿子小小的一句话，让我深深感动

★ 40岁年龄差，国王“迷弟”如何日常粉“爱豆”达•芬奇

★ 2009年BEC中级写作考试真题及答案